217 related articles for article (PubMed ID: 26608920)
21. Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer.
Gauttier V; Judor JP; Le Guen V; Cany J; Ferry N; Conchon S
Int J Cancer; 2014 Dec; 135(12):2857-67. PubMed ID: 24789574
[TBL] [Abstract][Full Text] [Related]
22. Tumor-specific CD4+ T cells develop cytotoxic activity and eliminate virus-induced tumor cells in the absence of regulatory T cells.
Akhmetzyanova I; Zelinskyy G; Schimmer S; Brandau S; Altenhoff P; Sparwasser T; Dittmer U
Cancer Immunol Immunother; 2013 Feb; 62(2):257-71. PubMed ID: 22890822
[TBL] [Abstract][Full Text] [Related]
23. Vaccination Produces CD4 T Cells with a Novel CD154-CD40-Dependent Cytolytic Mechanism.
Coler RN; Hudson T; Hughes S; Huang PW; Beebe EA; Orr MT
J Immunol; 2015 Oct; 195(7):3190-7. PubMed ID: 26297758
[TBL] [Abstract][Full Text] [Related]
24. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors.
Wilcox RA; Flies DB; Zhu G; Johnson AJ; Tamada K; Chapoval AI; Strome SE; Pease LR; Chen L
J Clin Invest; 2002 Mar; 109(5):651-9. PubMed ID: 11877473
[TBL] [Abstract][Full Text] [Related]
25. The CD137 Ligand Is Important for Type 1 Diabetes Development but Dispensable for the Homeostasis of Disease-Suppressive CD137
Foda BM; Ciecko AE; Serreze DV; Ridgway WM; Geurts AM; Chen YG
J Immunol; 2020 Jun; 204(11):2887-2899. PubMed ID: 32295876
[TBL] [Abstract][Full Text] [Related]
26. Agonistic anti-4-1BB antibody promotes the expansion of natural regulatory T cells while maintaining Foxp3 expression.
Zhang P; Gao F; Wang Q; Wang X; Zhu F; Ma C; Sun W; Zhang L
Scand J Immunol; 2007 Oct; 66(4):435-40. PubMed ID: 17850588
[TBL] [Abstract][Full Text] [Related]
27. Selective transduction of dendritic cells in human lymph nodes and superior induction of high-avidity melanoma-reactive cytotoxic T cells by a CD40-targeted adenovirus.
Hangalapura BN; Oosterhoff D; Aggarwal S; Wijnands PG; van de Ven R; Santegoets SJ; van den Tol MP; Hooijberg E; Pereboev A; van den Eertwegh AJ; Curiel DT; Scheper RJ; de Gruijl TD
J Immunother; 2010 Sep; 33(7):706-15. PubMed ID: 20664356
[TBL] [Abstract][Full Text] [Related]
28. Unified immune modulation by 4-1BB triggering leads to diverse effects on disease progression in vivo.
Choi BK; Kim YH; Choi JH; Kim CH; Kim KS; Sung YC; Lee YM; Moffett JR; Kwon BS
Cytokine; 2011 Sep; 55(3):420-8. PubMed ID: 21700476
[TBL] [Abstract][Full Text] [Related]
29. Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus.
DeBenedette MA; Wen T; Bachmann MF; Ohashi PS; Barber BH; Stocking KL; Peschon JJ; Watts TH
J Immunol; 1999 Nov; 163(9):4833-41. PubMed ID: 10528184
[TBL] [Abstract][Full Text] [Related]
30. 4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses.
Tan JT; Whitmire JK; Ahmed R; Pearson TC; Larsen CP
J Immunol; 1999 Nov; 163(9):4859-68. PubMed ID: 10528187
[TBL] [Abstract][Full Text] [Related]
31. Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor.
Shindo Y; Yoshimura K; Kuramasu A; Watanabe Y; Ito H; Kondo T; Oga A; Ito H; Yoshino S; Hazama S; Tamada K; Yagita H; Oka M
Anticancer Res; 2015 Jan; 35(1):129-36. PubMed ID: 25550543
[TBL] [Abstract][Full Text] [Related]
32. T cell costimulation with anti-CD137 monoclonal antibodies is mediated by K63-polyubiquitin-dependent signals from endosomes.
Martinez-Forero I; Azpilikueta A; Bolaños-Mateo E; Nistal-Villan E; Palazon A; Teijeira A; Perez-Chacon G; Morales-Kastresana A; Murillo O; Jure-Kunkel M; Zapata JM; Melero I
J Immunol; 2013 Jun; 190(12):6694-706. PubMed ID: 23690480
[TBL] [Abstract][Full Text] [Related]
33. Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion.
Teng MW; Swann JB; von Scheidt B; Sharkey J; Zerafa N; McLaughlin N; Yamaguchi T; Sakaguchi S; Darcy PK; Smyth MJ
Cancer Res; 2010 Apr; 70(7):2665-74. PubMed ID: 20332236
[TBL] [Abstract][Full Text] [Related]
34. A converse 4-1BB and CD40 ligand expression pattern delineates activated regulatory T cells (Treg) and conventional T cells enabling direct isolation of alloantigen-reactive natural Foxp3+ Treg.
Schoenbrunn A; Frentsch M; Kohler S; Keye J; Dooms H; Moewes B; Dong J; Loddenkemper C; Sieper J; Wu P; Romagnani C; Matzmohr N; Thiel A
J Immunol; 2012 Dec; 189(12):5985-94. PubMed ID: 23162126
[TBL] [Abstract][Full Text] [Related]
35. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
[TBL] [Abstract][Full Text] [Related]
36. Mitochondrial Morphological and Functional Reprogramming Following CD137 (4-1BB) Costimulation.
Teijeira A; Labiano S; Garasa S; Etxeberria I; Santamaría E; Rouzaut A; Enamorado M; Azpilikueta A; Inoges S; Bolaños E; Aznar MA; Sánchez-Paulete AR; Sancho D; Melero I
Cancer Immunol Res; 2018 Jul; 6(7):798-811. PubMed ID: 29678874
[TBL] [Abstract][Full Text] [Related]
37. Targeting spatiotemporal expression of CD137 on tumor-infiltrating cytotoxic T lymphocytes as a novel strategy for agonistic antibody therapy.
Noji S; Hosoi A; Takeda K; Matsushita H; Morishita Y; Seto Y; Kakimi K
J Immunother; 2012 Jul; 35(6):460-72. PubMed ID: 22735804
[TBL] [Abstract][Full Text] [Related]
38. Combinational immunotherapy for established tumors with engineered tumor vaccines and adenovirus-mediated gene transfer.
Xiang J; Chen Y; Moyana T
Cancer Gene Ther; 2000 Jul; 7(7):1023-33. PubMed ID: 10917205
[TBL] [Abstract][Full Text] [Related]
39. Foxp3+ T cells inhibit antitumor immune memory modulated by mTOR inhibition.
Wang Y; Sparwasser T; Figlin R; Kim HL
Cancer Res; 2014 Apr; 74(8):2217-28. PubMed ID: 24574514
[TBL] [Abstract][Full Text] [Related]
40. Intratumoral injection of interferon-α and systemic delivery of agonist anti-CD137 monoclonal antibodies synergize for immunotherapy.
Dubrot J; Palazón A; Alfaro C; Azpilikueta A; Ochoa MC; Rouzaut A; Martinez-Forero I; Teijeira A; Berraondo P; Le Bon A; Hervás-Stubbs S; Melero I
Int J Cancer; 2011 Jan; 128(1):105-18. PubMed ID: 20309938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
